Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 3/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953831 | 0.90 | PRKAG1 (0.47) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL18554248 | 0.84 | BCHE (0.56) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL176882 | 0.84 | PRKAG1 (0.66) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL16516393 | 0.82 | KDM4E (0.63) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL13069602 | 0.82 | JAK2 (0.51) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL3953836 | 0.80 | FLT3 (0.49) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL12583303 | 0.80 | YTHDC1 (0.60) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL492550 | 0.78 | KDM4E (0.64) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL10073863 | 0.78 | CYP1A2 (0.50) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL12582647 | 0.77 | SMN1; SMN2 (0.59) | FLT3CDK2NPC1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1581503-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060020000-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-01-26 | — | — | US | disclosed |
| EP-1581503-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043354-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020000-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | PRKAG1 1018/4885PRKAA1 2813/4885PRKAB1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.